Hepatic Failure in COVID-19: Is Iron Overload the Dangerous Trigger?


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
04 05 2021
Historique:
received: 17 02 2021
revised: 30 04 2021
accepted: 03 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 9 6 2021
Statut: epublish

Résumé

Liver injury in COVID-19 patients has progressively emerged, even in those without a history of liver disease, yet the mechanism of liver pathogenicity is still controversial. COVID-19 is frequently associated with increased serum ferritin levels, and hyperferritinemia was shown to correlate with illness severity. The liver is the major site for iron storage, and conditions of iron overload have been established to have a pathogenic role in development of liver diseases. We presented here six patients who developed severe COVID-19, with biochemical evidence of liver failure. Three cases were survived patients, who underwent liver biopsy; the other three were deceased patients, who were autopsied. None of the patients suffered underlying liver pathologies. Histopathological and ultrastructural analyses were performed. The most striking finding we demonstrated in all patients was iron accumulation into hepatocytes, associated with degenerative changes. Abundant ferritin particles were found enclosed in siderosomes, and large aggregates of hemosiderin were found, often in close contact with damaged mitochondria. Iron-caused oxidative stress may be responsible for mitochondria metabolic dysfunction. In agreement with this, association between mitochondria and lipid droplets was also found. Overall, our data suggest that hepatic iron overload could be the pathogenic trigger of liver injury associated to COVID-19.

Identifiants

pubmed: 34064487
pii: cells10051103
doi: 10.3390/cells10051103
pmc: PMC8147922
pii:
doi:

Substances chimiques

Antiviral Agents 0
Ferritins 9007-73-2
Iron E1UOL152H7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Associazione Unitaria Avvocati e Procuratori di Stato
ID : 000
Organisme : Ministero della Salute
ID : COVID-2020-12371817
Organisme : Ministero della Salute
ID : COVID-2020-12371675

Références

Mod Pathol. 2020 Nov;33(11):2147-2155
pubmed: 32792598
J Hepatol. 2020 Oct;73(4):991-992
pubmed: 32454042
Arch Med Res. 2020 Jul;51(5):384-387
pubmed: 32402576
Cell Death Dis. 2021 Mar 12;12(3):263
pubmed: 33712574
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
J Gastroenterol. 2021 Mar;56(3):218-230
pubmed: 33527211
Biochimie. 2015 Aug;115:203-11
pubmed: 26093100
Cells. 2020 May 09;9(5):
pubmed: 32397376
World J Gastroenterol. 2007 Sep 21;13(35):4746-54
pubmed: 17729396
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Mol Sci. 2019 Apr 30;20(9):
pubmed: 31052166
Respir Res. 2020 Oct 21;21(1):276
pubmed: 33087116
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Oxid Med Cell Longev. 2013;2013:327167
pubmed: 24175011
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
Cell. 2021 Feb 4;184(3):775-791.e14
pubmed: 33503446
Hepatology. 2011 Jul;54(1):328-43
pubmed: 21452290
Hepatology. 1983 Mar-Apr;3(2):232-5
pubmed: 6832714
Nat Rev Mol Cell Biol. 2021 Apr;22(4):266-282
pubmed: 33495651
J Clin Med. 2020 Jul 29;9(8):
pubmed: 32751400
J Pathol Bacteriol. 1962 Jul;84:53-64
pubmed: 14498313
Hepatology. 2020 Sep;72(3):807-817
pubmed: 32473607
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Liver Int. 2020 Aug;40(8):2038-2040
pubmed: 32352224
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Hepatology. 2021 Mar;73(3):890-900
pubmed: 32415860
Hepatol Int. 2020 Sep;14(5):723-732
pubmed: 33026573
Biochim Biophys Acta. 2006 May-Jun;1763(5-6):542-8
pubmed: 16730811
J Infect Dis. 2020 Nov 9;222(11):1807-1815
pubmed: 32914853
Antioxid Redox Signal. 2008 Aug;10(8):1313-42
pubmed: 18435594
Protein Cell. 2020 Oct;11(10):771-775
pubmed: 32303993
Physiol Rev. 2013 Oct;93(4):1721-41
pubmed: 24137020
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Chem Biol Interact. 2020 Oct 1;330:109230
pubmed: 32828744
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Am J Med Sci. 1991 Jan;301(1):32-43
pubmed: 1847276
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970

Auteurs

Franca Del Nonno (F)

Pathology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Roberta Nardacci (R)

Laboratory of Electron Microscopy, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Daniele Colombo (D)

Pathology Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Ubaldo Visco-Comandini (U)

Hepatology Unit "Lazzaoro Spallanzani"-IRCCS, 00149 Rome, Italy.

Stefania Cicalini (S)

HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Andrea Antinori (A)

HIV/AIDS Department, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Luisa Marchioni (L)

Clinical Department, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Gianpiero D'Offizi (G)

Hepatology Unit "Lazzaoro Spallanzani"-IRCCS, 00149 Rome, Italy.

Mauro Piacentini (M)

Laboratory of Electron Microscopy, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.
Department of Biology, University of Rome "Tor Vergata", 00133 Rome, Italy.

Laura Falasca (L)

Laboratory of Electron Microscopy, National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH